Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta1-induced connective tissue growth factor expression in rat hepatic stellate cells.
- Author:
Kai SUN
1
;
Xiao-Hui HUANG
;
Qian WANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Cells, Cultured; Connective Tissue Growth Factor; metabolism; Hepatic Stellate Cells; drug effects; metabolism; Oxazoles; pharmacology; PPAR gamma; pharmacology; RNA, Messenger; genetics; Rats; Signal Transduction; Transforming Growth Factor beta1; pharmacology; Tyrosine; analogs & derivatives; pharmacology
- From: Journal of Southern Medical University 2009;29(7):1354-1358
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of peroxisome proliferator-activated receptor gamma (PPARgamma) activation on transforming growth factor beta1 (TGF-beta1)-induced connective tissue growth factor (CTGF) expression in rat hepatic stellate cells (HSCs).
METHODSCultured HSCs with or without PPARgamma-specific antagonist GW9662 treatment prior to the addition of an increasing amount of PPARgamma natural ligand (15-d-PGJ2) or synthetic ligand (GW7845) were stimulated with TGF-beta1. The mRNA and protein levels of CTGF expression were detected by semi-quantitative RT-PCR and Western blotting, respectively. The morphological changes of the HSC were observed by electron microscope.
RESULTS15-d-PGJ2 and GW7845 significantly inhibited TGF-beta1-induced CTGF expression at both mRNA and protein levels in HSCs, and the inhibitory effect was dramatically, if not completely, abolished by pretreatment with GW9662, suggesting that the inhibition was mediated by PPARgamma. Morphological observation revealed that PPARgamma activation caused obvious changes of HSCs from activated to quiescent phenotypes.
CONCLUSIONPPARgamma ligand shows potent inhibitory effect on TGF-beta1-induced CTGF expression in rat HSCs, suggesting its potential as a candidate agent for treatment and prevention of hepatic fibrosis.
